... Your oncologist (cancer doctor) may recommend: Another targeted therapy, such as acalabrutinib (Calquence), pirtobrutinib (Jaypirca), venetoclax (Venclexta) — which is used off-label — or zanubrutinib (Brukinsa) Chimeric antigen receptor (CAR) T-cell therapy, such as brexucabtagene autoleucel (Tecartus) or lisocabtagene maraleucel (Breyanzi) Chemotherapies ...
... Your oncologist (cancer doctor) may recommend: Another targeted therapy, such as acalabrutinib (Calquence), pirtobrutinib (Jaypirca), venetoclax (Venclexta) — which is used off-label — or zanubrutinib (Brukinsa) Chimeric antigen receptor (CAR) T-cell therapy, such as brexucabtagene autoleucel (Tecartus) or lisocabtagene maraleucel (Breyanzi) Chemotherapies ...
... Most doctors treat SLL/CLL with targeted therapies first.Targeted therapy drugs, which may be used alone or in combinations, include: Acalabrutinib (Calquence) Bendamustine (Treanda) Ibrutinib (Imbruvica) Obinutuzumab (Gazyva) Ofatumumab (Azerra) Rituximab (Rituxan) Venetoclax (Venclexta) One important combination treatment is called FCR. ...
... Most doctors treat SLL/CLL with targeted therapies first.Targeted therapy drugs, which may be used alone or in combinations, include: Acalabrutinib (Calquence) Bendamustine (Treanda) Ibrutinib (Imbruvica) Obinutuzumab (Gazyva) Ofatumumab (Azerra) Rituximab (Rituxan) Venetoclax (Venclexta) One important combination treatment is called FCR. ...